The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- LDP Junior Lawmakers to Launch Vaccine Study Group
April 17, 2019
- Entyvio’s Crohn’s Disease Use on Agenda for April 26 MHLW Panel Meeting
April 15, 2019
- CEFP Kicks Off Discussions towards 2020 Reimbursement Policy Reform
April 11, 2019
- Dupixent to Join Self-Injectable Drug List
April 11, 2019
- Supply of MSD’s Hep B Vaccine Heptavax Might Be Suspended as Early as October: MHLW
April 10, 2019
- MHLW Informally Notifies Drug Makers of Post-Oct. 1 NHI Prices
April 9, 2019
- Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More
April 9, 2019
- Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review
April 8, 2019
- Epadel OTC to Be Reclassified as “Class 1” Category under Stricter Rules on Sales: MHLW Panel
April 5, 2019
- New Detailing Guidelines Take Effect on April 1; Q&A on Information Supply on Unapproved Drugs/Indications Issued
April 2, 2019
- MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs
April 1, 2019
- PMDA Conducting Risk Review for Suglat, Forxiga, Opdivo, and More
April 1, 2019
- MHLW Orders Shift from “Relative Contraindications” to “Contraindications” in Labels of Hypnotics, Antibiotics and More
April 1, 2019
- PMDA Reprimands 3 Senior Officials after Employee Dismissal
April 1, 2019
- Kymriah, Collategene to Follow Drug Listing Pathway: Chuikyo
March 28, 2019
- Chuikyo Reps Want Early Debate for 2020 Drug Price Revision; Polypharmacy, Formulary Also on Agenda
March 28, 2019
- Chuikyo OKs Details of Cost-Effectiveness Assessment Scheme
March 28, 2019
- Chuikyo OKs 70% Pricing for Nesp Biosame; New Rules Up for FY2020 Reform Debate
March 28, 2019
- Opdivo Up for Yet Another Re-Pricing after CEA Confirmatory Analysis, but New Price Undisclosed
March 28, 2019
- National Cancer Center’s Fujiwara Named New PMDA Chief
March 27, 2019
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…